Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

803.17 +19.52 (+2.49%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Regeneron Pharmaceuticals

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
49 50 Next >
News headline image
Regeneron-Sanofi's Flagship Dupixent Becomes First FDA-Approved Treatment For Prurigo Nodularis ↗
 
Via Benzinga
News headline image
Ocular Therapeutix's Wet AMD Candidate Shows Sustained, Comparable Clinical Activity Vs. Eylea ↗
 
Via Benzinga
News headline image
The 7 Best Stocks to Buy to Tap Into a Hidden Bull Market ↗
Despite the ongoing worries on Wall Street, these are the best stocks to buy to play the hidden bull market. 
Via InvestorPlace
News headline image
Can Healthcare Stocks Continue To Outperform? ↗
Large-cap healthcare and biotech stocks have been resilient amidst the market turmoil caused by rising rates and the global geopolitical crisis. 
Via Talk Markets
News headline image
The Top 5 Stocks Cathie Wood Is Buying This Week ↗
Cathie Wood announced that she would step down as portfolio manager for PRNT and IZRL. That hasn't stopped her from making her usual buys. 
Via InvestorPlace
News headline image
Regeneron's Bispecific Antibodies Show Encouraging Anti Tumor Activity ↗
 
Via Benzinga
News headline image
Analyst Ratings for Regeneron Pharmaceuticals ↗
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings: 
Via Benzinga
News headline image
Ionis Pharmaceuticals Nosedives After AstraZeneca Drops High Cholesterol Drug Test ↗
Though successful in early testing, it wasn't enough to win a Phase 3 study. 
Via Investor's Business Daily
News headline image
$100 Invested In This Stock 10 Years Ago Would Be Worth $500 Today ↗
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 10 years by 6.71% on an annualized basis producing an average annual return of 16.96%. Currently, Regeneron... 
Via Benzinga
News headline image
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders ↗
 
Via Benzinga
News headline image
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete ↗
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. 
Via Benzinga
News headline image
Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies ↗
 
Via Benzinga
News headline image
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing ↗
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
News headline image
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
News headline image
Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers ↗
 
Via Benzinga
News headline image
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing ↗
 
Via Benzinga
News headline image
ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients ↗
 
Via Benzinga
News headline image
Biden Administration Pushes 'Cancer Moonshot' Initiative: Report ↗
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it."  The... 
Via Benzinga
News headline image
A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says ↗
Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rati 
Via Benzinga
News headline image
9 Analysts Have This to Say About Regeneron Pharmaceuticals ↗
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter: 
Via Benzinga
News headline image
Jefferies Upgrades Regeneron Pharmaceuticals: Here's What You Need To Know ↗
Jefferies upgraded its rating of Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold with a price target of $675.00, changing its price target from $536.00 to $675.00. Shares of Regeneron Pharmaceuticals... 
Via Benzinga
News headline image
'Highly Compelling' Eye Drug Data Has Wall Street Stampeding To Buy This 'Large Cap Growth Story.' Even After $15B In Market Cap Was Added ↗
 
Via Benzinga
News headline image
What 9 Analyst Ratings Have To Say About Regeneron Pharmaceuticals ↗
Over the past 3 months, 9 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Regeneron Pharmaceuticals To $851? Here Are 5 Other Price Target Changes For Friday ↗
Morgan Stanley raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) from $625 to $851. Morgan Stanley analyst Matthew Harrison also upgraded the stock from Equal-Weight to... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗
Upgrades 
Via Benzinga
News headline image
US Stock Futures Surge; Fed Speakers In Focus ↗
Pre-open movers U.S. stock futures traded higher in early pre-market trade after recording gains on Thursday. The Dow Jones jumped around 193 points, while the Nasdaq Composite climbed 0.6% in the... 
Via Benzinga
News headline image
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday ↗
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to... 
Via Benzinga
News headline image
Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease ↗
 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.